R. Delva

5.7k total citations · 1 hit paper
99 papers, 2.5k citations indexed

About

R. Delva is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, R. Delva has authored 99 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Pulmonary and Respiratory Medicine, 54 papers in Oncology and 28 papers in Cancer Research. Recurrent topics in R. Delva's work include Cancer Treatment and Pharmacology (32 papers), Prostate Cancer Treatment and Research (28 papers) and Renal cell carcinoma treatment (17 papers). R. Delva is often cited by papers focused on Cancer Treatment and Pharmacology (32 papers), Prostate Cancer Treatment and Research (28 papers) and Renal cell carcinoma treatment (17 papers). R. Delva collaborates with scholars based in France, United States and Belgium. R. Delva's co-authors include Érick Gamelin, M. Boisdron‐Celle, Alain Morel, Christine Chevreau, Véronique Guerin‐Meyer, Norbert Ifrah, Gwénaëlle Gravis, Alain Lortholary, F Larra and Sylvie Négrier and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer.

In The Last Decade

R. Delva

96 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

2015 315 citations Gwénaëlle Gravis, Jean‐Marie Boher et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. Delva France	21	1.3k	1.3k	657	538	395	99	2.5k
Giacomo Cartenì Italy	27	1.7k 1.4×	1.4k 1.2×	648 1.0×	521 1.0×	864 2.2×	110	3.2k
Roberto Petrioli Italy	28	1.6k 1.3×	1.2k 1.0×	508 0.8×	407 0.8×	855 2.2×	135	3.1k
Stephen Shibata United States	28	1.2k 0.9×	601 0.5×	433 0.7×	226 0.4×	545 1.4×	84	2.2k
Ingrid M.E. Desar Netherlands	28	1.2k 1.0×	1.2k 1.0×	751 1.1×	306 0.6×	285 0.7×	158	2.7k
Luigi Manzione Italy	29	2.4k 1.9×	1.3k 1.0×	386 0.6×	394 0.7×	637 1.6×	88	3.4k
Jean‐Emmanuel Kurtz France	28	891 0.7×	1.1k 0.9×	420 0.6×	248 0.5×	364 0.9×	113	2.6k
P. Fargeot France	30	1.7k 1.4×	575 0.5×	355 0.5×	899 1.7×	564 1.4×	87	2.7k
J. L. Misset France	27	2.1k 1.7×	1.0k 0.8×	433 0.7×	566 1.1×	452 1.1×	63	3.0k
Muhammad Wasif Saif United States	25	1.7k 1.4×	639 0.5×	562 0.9×	222 0.4×	475 1.2×	129	2.7k
Jean‐Paul Guastalla France	31	2.2k 1.7×	495 0.4×	621 0.9×	674 1.3×	521 1.3×	109	3.7k

Countries citing papers authored by R. Delva

Since Specialization

Citations

This map shows the geographic impact of R. Delva's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. Delva with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. Delva more than expected).

Fields of papers citing papers by R. Delva

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. Delva. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. Delva. The network helps show where R. Delva may publish in the future.

Co-authorship network of co-authors of R. Delva

This figure shows the co-authorship network connecting the top 25 collaborators of R. Delva. A scholar is included among the top collaborators of R. Delva based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. Delva. R. Delva is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Grenga, Lucia, Catherine Dunyach‐Remy, Guilhem Roubaud, et al.. (2025). Gut microbiota as a biomarker for the efficacy of pembrolizumab in patients with advanced urothelial carcinoma treated in a prospective multicenter study.. Journal of Clinical Oncology. 43(5_suppl). 825–825. 1 indexed citations

Bono, Johann S. de, Alexander Laird, Philippe Barthélémy, et al.. (2025). Talazoparib Monotherapy in Metastatic Castration-resistant Prostate Cancer with DNA Damage Response Alterations—Genomic Features Associated with Response to Therapy. European Urology Oncology. 8(6). 1617–1628.

Fizazi, Karim, Gwénaël Le Teuff, Aude Fléchon, et al.. (2024). Personalized Chemotherapy on the Basis of Tumor Marker Decline in Poor-Prognosis Germ-Cell Tumors: Updated Analysis of the GETUG-13 Phase III Trial. Journal of Clinical Oncology. 42(28). 3270–3276. 4 indexed citations

Bono, Johann S. de, Alexander Laird, Philippe Barthélémy, et al.. (2021). 580P TALAPRO-1: Talazoparib (TALA) monotherapy in metastatic castration-resistant prostate cancer (mCRPC) with DNA damage response alterations (DDRm) - Exploration of non-DDR mutational landscape and potential associations with antitumor activity. Annals of Oncology. 32. S630–S631. 1 indexed citations

Siefker‐Radtke, Arlene O., Yohann Loriot, Salvatore Siena, et al.. (2020). 752P Updated data from the NORSE trial of erdafitinib (ERDA) plus cetrelimab (CET) in patients (pts) with metastatic or locally advanced urothelial carcinoma (mUC) and specific fibroblast growth factor receptor (FGFR) alterations. Annals of Oncology. 31. S584–S585. 8 indexed citations

Chevreau, Christine, Sophie Broutin, Jérôme Guitton, et al.. (2017). Therapeutic Drug Monitoring of Carboplatin in High-Dose Protocol (TI-CE) for Advanced Germ Cell Tumors: Pharmacokinetic Results of a Phase II Multicenter Study. Clinical Cancer Research. 23(23). 7171–7179. 14 indexed citations

Linassier, Claude, Laurence Albigès, Christine Chevreau, et al.. (2016). Everolimus and sunitinib as first- and second-line treatments of patients with metastatic papillary renal cell carcinoma (pRCC): A retrospective study of the GETUG (Groupe Français d’Etude des Tumeurs Uro-Génitales).. Journal of Clinical Oncology. 34(2_suppl). 505–505. 1 indexed citations

Gonçalvès, Anthony, Jean‐Yves Pierga, Jean-Marc Ferrero, et al.. (2015). UNICANCER-PEGASE 07 study: a randomized phase III trial evaluating postoperative docetaxel–5FU regimen after neoadjuvant dose-intense chemotherapy for treatment of inflammatory breast cancer. Annals of Oncology. 26(8). 1692–1697. 14 indexed citations

Pierga, Jean‐Yves, R. Delva, Xavier Pivot, et al.. (2014). Bévacizumab et taxanes dans le traitement de première ligne du cancer du sein métastatique: survie globale et analyse de sous-groupes de l’étude ATHENA France. Bulletin du Cancer. 101(9). 780–788. 3 indexed citations

10.

Hardy‐Bessard, Anne‐Claire, R. Delva, Xavier Pivot, et al.. (2012). Tolérance et efficacité du bévacizumab en association aux taxanes en première ligne dans le cancer du sein métastatique : étude ATHENA-France. Bulletin du Cancer. 99(6). 609–618. 8 indexed citations

11.

Azria, D., Christophe Massard, Diégo Tosi, et al.. (2012). An ambispective observational study in the safety and efficacy of abiraterone acetate in the French temporary authorizations for use (ATU): Predictive parameters of response.. Journal of Clinical Oncology. 30(5_suppl). 149–149. 19 indexed citations

12.

Dièras, Véronique, Alain Lortholary, Valérie Laurence, et al.. (2012). Cabazitaxel in patients with advanced solid tumours: Results of a Phase I and pharmacokinetic study. European Journal of Cancer. 49(1). 25–34. 47 indexed citations

13.

Culine, Stéphane, Andrew Kramar, Christine Théodore, et al.. (2008). Randomized Trial Comparing Bleomycin/Etoposide/Cisplatin With Alternating Cisplatin/Cyclophosphamide/Doxorubicin and Vinblastine/Bleomycin Regimens of Chemotherapy for Patients With Intermediate- and Poor-Risk Metastatic Nonseminomatous Germ Cell Tumors: Genito-Urinary Group of the French Federation of Cancer Centers Trial T93MP. Journal of Clinical Oncology. 26(3). 421–427. 59 indexed citations

14.

Melichar, Bohuslav, P. Koralewski, Alain Ravaud, et al.. (2008). First-line bevacizumab combined with reduced dose interferon-α2a is active in patients with metastatic renal cell carcinoma. Annals of Oncology. 19(8). 1470–1476. 71 indexed citations

15.

Viens, Patrice, Thierry Petit, Alejandro Yovine, et al.. (2006). A phase II study of a paclitaxel and oxaliplatin combination in platinum-sensitive recurrent advanced ovarian cancer patients. Annals of Oncology. 17(3). 429–436. 31 indexed citations

16.

Gonçalves, A., R. Delva, Michel Fabbro, et al.. (2006). Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study. Bone Marrow Transplantation. 37(7). 651–659. 2 indexed citations

17.

Lotz, Jean‐Pierre, B. Bui, F. Gómez, et al.. (2005). Sequential high-dose chemotherapy protocol for relapsed poor prognosis germ cell tumors combining two mobilization and cytoreductive treatments followed by three high-dose chemotherapy regimens supported by autologous stem cell transplantation. Results of the phase II multicentric TAXIF trial. Annals of Oncology. 16(3). 411–418. 39 indexed citations

18.

Viens, Patrice, Thomas Petit, Alejandro Yovine, et al.. (2004). Phase II trial of oxaliplatin (OXA) combined with paclitaxel (P) inplatinum + taxanes sensitive advanced ovarian cancer (AOC) patients: Final results. Journal of Clinical Oncology. 22(14_suppl). 5023–5023. 6 indexed citations

19.

Boisdron‐Celle, M., et al.. (2002). Influence of oxaliplatin on 5-fluorouracil plasma clearance and clinical consequences. Cancer Chemotherapy and Pharmacology. 49(3). 235–243. 18 indexed citations

20.

Delva, R., Érick Gamelin, Alain Lortholary, et al.. (1998). Suppression of heparinization of central venous catheters between cycles of chemotherapy. Supportive Care in Cancer. 6(4). 384–388. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact